专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06576463B1 Hybrid vectors for gene therapy 有权
标题翻译：用于基因治疗的杂交载体
公开(公告)号：US06576463B1
公开(公告)日：2003-06-10
申请号：US09484901
申请日：2000-01-18
申请人： Noriyuki Kasahara , Collin Higo , Harris Soifer , Kohnosuke Mitani
发明人： Noriyuki Kasahara , Collin Higo , Harris Soifer , Kohnosuke Mitani
IPC分类号： C12N1586
CPC分类号： C12N15/86 , A61K48/00 , C12N2710/10343 , C12N2710/10344 , C12N2800/30 , C12N2800/90 , C12N2840/20 , C12N2840/44
摘要： The invention discloses hybrid vectors for delivering genes or other nucleic acids into mammalian cells. The hybrid vectors of the invention contain both a helper dependent adenoviral portion and a second portion derived from either a replication incompetent retrovirus or from a transposon. Such vectors provide efficient transduction of quiescent cells and provide for stable integration of the gene to be delivered.
摘要翻译：本发明公开了用于将基因或其他核酸递送到哺乳动物细胞中的杂交载体。本发明的杂交载体含有辅助依赖性腺病毒部分和衍生自复制无能逆转录病毒或转座子的第二部分。这样的载体提供了静止细胞的有效转导并且提供待传递的基因的稳定整合。

2. 发明授权

US06461869B1 Purging leukemia cells from hematopoietic stem cells 失效
标题翻译：从造血干细胞清除白血病细胞
公开(公告)号：US06461869B1
公开(公告)日：2002-10-08
申请号：US09357752
申请日：1999-07-20
申请人： Paul Schwarzenberger , Jay Kolls
发明人： Paul Schwarzenberger , Jay Kolls
IPC分类号： C12N1586
CPC分类号： C12N5/0093 , A61K2035/124 , C12N5/0647 , C12N5/0694
摘要： A gene therapy system is disclosed that selectively kills leukemia cells in bone marrow, while leaving stem cells unaffected. All cells in a mixture of stem cells and leukemia cells are transfected with a high efficiency gene transfer vector. The vector carries a eukaryotic expression construct encoding a toxin gene. This toxin gene is expressed only in leukemia cells, not in stem cells. Differential expression of the toxin gene in leukemia cells and stem cells may be achieved by placing the coding sequence under the control of an appropriate promoter, such as the RSV promoter or the SV40 promoter. High gene expression has been demonstrated in a panel of transformed leukemia cell lines, but no gene expression in transformed, CD34-selected, primary human stem cells. The treatment will be useful not only for leukemia patients, but also for other cancer patients undergoing autologous bone marrow transplants (e.g., breast or lymphoma cancers).
摘要翻译：公开了一种基因治疗系统，其选择性地杀死骨髓中的白血病细胞，同时使干细胞不受影响。用高效率的基因转移载体转染干细胞和白血病细胞混合物中的所有细胞。载体携带编码毒素基因的真核表达构建体。这种毒素基因仅在白血病细胞中表达，而不是在干细胞中表达。毒素基因在白血病细胞和干细胞中的差异表达可以通过将编码序列置于合适的启动子如RSV启动子或SV40启动子的控制下来实现。已经在一组转化的白血病细胞系中证实了高基因表达，但是在转化的CD34选择的原代人干细胞中没有基因表达。该治疗不仅对白血病患者有用，而且对于经历自体骨髓移植（例如乳腺癌或淋巴瘤）的其它癌症患者也是有用的。

3. 发明授权

US06455314B1 Alternatively targeted adenovirus 有权
标题翻译：或者靶向腺病毒
公开(公告)号：US06455314B1
公开(公告)日：2002-09-24
申请号：US09393627
申请日：1999-09-10
申请人： Thomas J. Wickham , Imre Kovesdi , Petrus W. Roelvink , Joseph T. Bruder
发明人： Thomas J. Wickham , Imre Kovesdi , Petrus W. Roelvink , Joseph T. Bruder
IPC分类号： C12N1586
CPC分类号： C07K14/005 , A61K48/00 , C12N15/86 , C12N2710/10322 , C12N2710/10343 , C12N2710/10345 , C12N2810/40 , C12N2810/405 , C12N2810/6018 , C12N2830/008
摘要： The present invention provides a recombinant protein having an amino terminus of an adenoviral fiber protein and having a trimerization domain. A fiber incorporating such a protein exhibits reduced affinity for a native substrate than does a wild-type adenoviral fiber trimer. The present invention further provides an adenovirus incorporating the recombinant protein of the present invention.
摘要翻译：本发明提供具有腺病毒纤维蛋白的氨基末端并具有三聚结构域的重组蛋白质。与野生型腺病毒纤维三聚体相比，掺入这种蛋白质的纤维对天然底物的亲和性降低。本发明还提供了并入本发明的重组蛋白的腺病毒。

4. 发明授权

US06451596B1 Helper adenovirus vectors 有权
标题翻译：辅助腺病毒载体
公开(公告)号：US06451596B1
公开(公告)日：2002-09-17
申请号：US09562919
申请日：2000-05-02
申请人： Jeffrey S. Chamberlain , Andrea Amalfitano , Michael A. Hauser , Rajendra Kumar-Singh , Denis J. Hartigan-O'Connor
发明人： Jeffrey S. Chamberlain , Andrea Amalfitano , Michael A. Hauser , Rajendra Kumar-Singh , Denis J. Hartigan-O'Connor
IPC分类号： C12N1586
CPC分类号： C12N15/86 , A61K48/00 , C07K14/4708 , C12N7/00 , C12N2710/10343 , C12N2800/30 , C12N2830/008 , C12N2830/30
摘要： The present invention provides improved adenovirus vectors and packaging cell lines. One type of improved adenoviral vector comprises deletions within the E2b region of the adenoviral genome. These E2b-deleted virus are used in conjunction with novel cell lines that constitutively express E2b gene products. The present invention further provides adenoviral vectors deleted for all viral coding regions. These “gutted” vectors permit the transfer of large genes to cells as demonstrated herein by the transfer of the dystrophin gene to the muscle of mice. The E2b-deleted vectors and the gutted vectors provide improved adenoviral vectors useful for a wide variety of gene therapy applications.
摘要翻译：本发明提供了改进的腺病毒载体和包装细胞系。一种类型的改良的腺病毒载体包含在腺病毒基因组的E2b区域内的缺失。这些E2b缺失的病毒与组成型表达E2b基因产物的新型细胞系一起使用。本发明还提供了所有病毒编码区缺失的腺病毒载体。这些“内含”载体允许将大基因转移到细胞中，如本文通过将肌营养不良蛋白基因转移到小鼠的肌肉所证明的。 E2b缺失的载体和内切的载体提供了可用于各种基因治疗应用的改良的腺病毒载体。

5. 发明授权

US06323024B1 Coxsackie virus vectors for delivery of nucleic acids encoding antigenic or therapeutic products 失效
标题翻译：用于递送编码抗原或治疗产物的核酸的柯萨奇病毒载体
公开(公告)号：US06323024B1
公开(公告)日：2001-11-27
申请号：US09403672
申请日：2000-03-27
申请人： Steven M. Tracy , Nora M. Chapman , Peter Kolbeck , James M. Malone, III
发明人： Steven M. Tracy , Nora M. Chapman , Peter Kolbeck , James M. Malone, III
IPC分类号： C12N1586
CPC分类号： C12N15/86 , A61K38/2026 , A61K38/2066 , A61K39/12 , A61K39/125 , A61K2039/5254 , A61K2039/5256 , A61K2039/57 , C12N2770/32334 , C12N2770/32343 , C12N2770/32362 , C12N2770/32644 , C12N2810/609 , Y02A50/466
摘要： The present invention is drawn to the use of attenuated Coxsackievirus cardiotropic virus vectors as efficient gene transfer vectors to deliver immunomodulatory or other biologically active proteins and/or antigenic epitopes in transient infections to aid in preventing, ameliorating, and/or ablating infectious viral heart disease and reducing, or ablating entirely, heart transplant rejection. Additionally, other organs or tissues may be targeted with specific picornaviruses. In particular, an attenuated CVB3 viral vector able to express a cytokine is provided. This cytokine-expressing viral vector is able to deliver the cytokine to a target tissue and reduce disease symptoms.
摘要翻译：本发明涉及使用减毒的柯萨奇病毒心脏病毒载体作为有效的基因转移载体，以在短暂感染中递送免疫调节或其他生物活性蛋白和/或抗原表位，以帮助预防，改善和/或消除感染性病毒性心脏病并减少或完全消除心脏移植排斥反应。此外，其他器官或组织可能被靶向为特定的细小核糖核酸病毒。特别地，提供能够表达细胞因子的减毒CVB3病毒载体。这种表达细胞因子的病毒载体能够将细胞因子递送至靶组织并减少疾病症状。

6. 发明授权

US06300129B1 Transgenic non-human animals for producing heterologous antibodies 失效
标题翻译：用于产生异源抗体的转基因非人动物
公开(公告)号：US06300129B1
公开(公告)日：2001-10-09
申请号：US08758417
申请日：1996-12-02
申请人： Nils Lonberg , Robert M. Kay
发明人： Nils Lonberg , Robert M. Kay
IPC分类号： C12N1586
CPC分类号： C12N15/8509 , A01K67/0276 , A01K67/0278 , A01K2207/15 , A01K2217/00 , A01K2217/05 , A01K2217/072 , A01K2217/075 , A01K2227/105 , A01K2267/01 , A01K2267/025 , A61K38/00 , C07K14/7051 , C07K16/00 , C07K16/2812 , C07K16/3007 , C07K16/4266 , C07K16/4291 , C07K16/44 , C07K16/462 , C07K2317/21 , C07K2317/24 , C07K2317/52 , C07K2317/56 , C07K2317/76 , C07K2319/00 , C12N5/163 , C12N15/00 , C12N15/113 , C12N15/85 , C12N15/87 , C12N15/90 , C12N15/907 , C12N2800/206 , C12N2800/70 , C12N2830/30 , C12N2830/36 , C12N2830/85
摘要： The invention relates to transgenic non-human animals capable of producing heterologous antibodies and methods for producing human sequence antibodies which bind to human antigens with substantial affinity.
摘要翻译：本发明涉及能够产生异源抗体的转基因非人动物和用于产生以大量亲和力结合人抗原的人序列抗体的方法。

7. 发明授权

US06825039B2 Plant pyruvate dehydrogenase kinase gene 失效
标题翻译：植物丙酮酸脱氢酶激酶基因
公开(公告)号：US06825039B2
公开(公告)日：2004-11-30
申请号：US10202428
申请日：2002-07-23
申请人： Jitao Zou , David C. Taylor
发明人： Jitao Zou , David C. Taylor
IPC分类号： C12N1586
CPC分类号： C12N9/1205 , C12N15/8243 , C12N15/8247 , C12N15/8261 , C12N15/827 , Y02A40/146
摘要： The present invention relates to the isolation, purification, characterization and use of a mitochondrial pyruvate dehydrogenase kinase (PDHK) gene (SEQ ID NO:1) (pYA5; ATCC No 209562) from the Brassicaceae (specifically Arabidopsis thaliana). The invention includes isolated and purified DNA of the stated sequence and relates to methods of regulating fatty acid synthesis, seed oil content, seed size/weight, flowering time, vegetative growth, respiration rate and generation time using the gene and to tissues and plants transformed with the gene. The invention also relates to transgenic plants, plant tissues and plant seeds having a genome containing an introduced DNA sequence of SEQ ID NO:1, or a part of SEQ ID NO:1 characterized in that said sequence has been introduced in an anti-sense or sense orientation, and a method of producing such plants and plant seeds. The invention also relates to substantially homologous DNA sequences from plants encoding proteins with deduced amino acid sequences of 25% or greater identity, and 50% or greater similarity, isolated and/or characterized by known methods using the sequence information of SEQ ID NO:1, and to parts of reduced length that are still able to function as inhibitors of gene expression by use in an anti-sense, co-suppression or other gene silencing technologies.
摘要翻译：本发明涉及来自十字花科（特别是拟南芥属）的线粒体丙酮酸脱氢酶激酶（PDHK）基因（SEQ ID NO：1）（pYA5; ATCC No 209562）的分离，纯化，表征和应用。本发明包括所述序列的分离和纯化的DNA，并且涉及调节脂肪酸合成，种子油含量，种子大小/重量，开花时间，营养生长，呼吸速率和使用该基因和组织和植物转化的产生时间的方法与基因。本发明还涉及具有包含SEQ ID NO：1的引入的DNA序列或SEQ ID NO：1的部分的基因组的转基因植物，植物组织和植物种子，其特征在于所述序列被引入反义或感觉取向，以及生产这种植物和植物种子的方法。本发明还涉及来自编码具有25％或更高同一性的推定的氨基酸序列的蛋白质的植物的基本上同源的DNA序列，以及50％或更多相似性的分离和/或通过使用SEQ ID NO：1的序列信息的已知方法，以及通过用于反义，共抑制或其他基因沉默技术仍然能够用作基因表达抑制剂的减少长度的部分。

8. 发明授权

US06770479B1 Anthrax vaccine 有权
标题翻译：炭疽疫苗
公开(公告)号：US06770479B1
公开(公告)日：2004-08-03
申请号：US09350729
申请日：1999-07-09
申请人： John S. Lee , Peter Pushko , Michael D. Parker , Jonathan F. Smith , Susan L. Welkos
发明人： John S. Lee , Peter Pushko , Michael D. Parker , Jonathan F. Smith , Susan L. Welkos
IPC分类号： C12N1586
CPC分类号： C07K14/32 , A61K2039/5256 , A61K2039/5258 , A61K2039/53 , C07K14/31 , C12N2799/021
摘要： Using the nontoxic PA protein from B. anthracis, a method and composition for use in inducing an immune response which is protective against anthrax in subjects is described.
摘要翻译：使用来自炭疽杆菌的无毒PA蛋白，描述了用于诱导受试者中对炭疽病有保护作用的免疫应答的方法和组合物。

9. 发明授权

US06495143B2 Botulinum neurotoxin vaccine 失效
标题翻译：肉毒杆菌神经毒素疫苗
公开(公告)号：US06495143B2
公开(公告)日：2002-12-17
申请号：US09350756
申请日：1999-07-09
申请人： John S. Lee , Peter Pushko , Jonathan F. Smith , Michael Parker , Mark T. Dertzbaugh , Leonard Smith
发明人： John S. Lee , Peter Pushko , Jonathan F. Smith , Michael Parker , Mark T. Dertzbaugh , Leonard Smith
IPC分类号： C12N1586
CPC分类号： C07K14/32 , A61K2039/5256 , A61K2039/5258 , A61K2039/53 , C07K14/31 , C07K14/33 , C12N2799/021
摘要： Using the nontoxic heavy chain fragment from botulinum neurotoxins A-G, compositions and methods of use in inducing an immune response which is protective against intoxication with botulinum in subjects is described.
摘要翻译：使用来自肉毒杆菌神经毒素A-G的无毒重链片段，描述了用于诱导免疫应答的组合物和方法，其在受试者中与肉毒杆菌中毒。

10. 发明授权

US06479279B2 Episomal vectors and uses thereof 有权
标题翻译：上皮样载体及其用途
公开(公告)号：US06479279B2
公开(公告)日：2002-11-12
申请号：US09101068
申请日：1998-09-28
申请人： Mart Ustav
发明人： Mart Ustav
IPC分类号： C12N1586
CPC分类号： C07K14/005 , A01K2217/05 , C12N15/86 , C12N2710/20022 , C12N2800/108 , C12N2820/60
摘要： The invention relates to a recombinant vector for stable persistence of exogenous DNA in a eukaryotic cell, and the uses of the recombinant vector for long-term stable production of gene product in the host cell, the vector including the minichromosomal maintenance element of papillomavirus.
摘要翻译：本发明涉及用于在真核细胞中稳定保持外源DNA的重组载体，以及重组载体用于宿主细胞中基因产物长期稳定产生的用途，载体包括乳头瘤病毒的染色体维持元件。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式